Provided by Tiger Trade Technology Pte. Ltd.

Alnylam Pharmaceuticals

224.41
+0.47000.21%
Post-market: 224.410.00000.00%16:26 EDT
Volume:1.06M
Turnover:240.26M
Market Cap:29.94B
PE:39.94
High:230.42
Open:224.39
Low:222.46
Close:223.94
52wk High:495.55
52wk Low:197.81
Shares:133.43M
Float Shares:133.16M
Volume Ratio:0.72
T/O Rate:0.80%
Dividend:- -
Dividend Rate:- -
EPS(TTM):5.62
EPS(LYR):2.33
ROE:96.55%
ROA:12.34%
PB:22.11
PE(LYR):96.31

Loading ...

NASDAQ Top and Bottom Performing Stocks at About 02:45 P.m. EDT on 2026-10-02

Reuters
·
Oct 03

NASDAQ Top and Bottom Performing Stocks at About 02:45 P.m. EDT on 2026-10-01

Reuters
·
Oct 02

Movement Alert|Alnylam Pharmaceuticals Falls 5.13% in Regular Trading, Multiple Banks Cut Price Targets Pressuring Sentiment

Market Focus
·
Oct 01

Compass Pathways Names Kelley Boucher Chief People Officer

Reuters
·
Sep 30

US Research Roundup-Alnylam Pharmaceuticals, Carvana, MongoDB

Reuters
·
Sep 30

Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY) and Revvity (RVTY)

TIPRANKS
·
Sep 26

Alnylam Pharmaceuticals Price Target Maintained with a $455.00/Share by HC Wainwright & Co.

Dow Jones
·
Sep 21

Analysts Offer Insights on Healthcare Companies: Innate Pharma (IPHA) and Alnylam Pharma (ALNY)

TIPRANKS
·
Sep 21

Analysts’ Top Healthcare Picks: Alnylam Pharma (ALNY), Scholar Rock Holding (SRRK)

TIPRANKS
·
Sep 16

NASDAQ Top and Bottom Performing Stocks at About 11:01 A.m. EDT on 2026-09-15

Reuters
·
Sep 15

Alnylam Pharmaceuticals Price Target Raised to $260.00/Share from $230.00 by Jefferies

Dow Jones
·
Sep 08

Movement Alert|Alnylam Pharmaceuticals Falls 5.3% in Pre-Market Trading, Trading at $251.34

Market Focus
·
Sep 08

Alnylam price target raised to $260 from $230 at Jefferies

TIPRANKS
·
Sep 08

Alnylam's Zilebesiran Sees Commercial Opportunity From Baxfendy Launch, Oppenheimer Says

MT Newswires Live
·
Sep 04

NASDAQ Top and Bottom Performing Stocks at About 02:45 P.m. EDT on 2026-09-02

Reuters
·
Sep 03

Alnylam Pharmaceuticals Inc Stock (ALNY) Moved Up by 7.90% on Sep 2: Facts Behind the Movement

TradingKey
·
Sep 03

Movement Alert|Alnylam Pharmaceuticals Rises 5.22% in Regular Trading, Competitor Data Setback and Analyst Optimism on Next-Gen Pipeline

Market Focus
·
Sep 02

Alnylam to Webcast Investor Conference Presentations in September

Reuters
·
Sep 02

Alnylam Pharmaceuticals Price Target Maintained with a $455.00/Share by HC Wainwright & Co.

Dow Jones
·
Sep 02

Alnylam's Latest Data Strengthen Outlook for Nucresiran, TRITON-CM, Oppenheimer Says

MT Newswires Live
·
Aug 31